Daruharidra

Names and identification

Language	Name
English	Daruharidra
Latin/Botanical	Berberis aristata DC.

Key Phytochemical Constituents

• Berberine (isoquinoline alkaloid - primary bioactive compound)
• Palmatine (protoberberine alkaloid)
• Jatrorrhizine
• Oxyberberine
• Berbamine (bisbenzylisoquinoline alkaloid)
• Karachine
• Taxilamine
• Tannins and phenolic acids

How does it work?

• JAK1/STAT1 pathway suppression: Berberine inhibits the JAK1/STAT1 signaling cascade, reducing keratinocyte hyperproliferation and inflammatory cytokine production in psoriasis
• MMP-1 and MMP-9 inhibition for anti-aging: Berberine inhibits UV-induced MMP-1 and MMP-9 expression, prevents TPA-induced ERK activation and AP-1 DNA binding, protecting collagen and extracellular matrix from degradation
• Anti-tyrosinase skin lightening: Berberine and Berberis aristata extracts inhibit tyrosinase enzyme activity, reducing melanin biosynthesis for skin lightening and hyperpigmentation correction
• Anti-microbial S. aureus inhibition: Berberine inhibits Staphylococcus aureus colonization and mast cell degranulation, particularly relevant for eczema management where bacterial infection exacerbates symptoms

Which traditional uses are supported by research?

• Skin diseases and acne (Kushtha/Yauvanpidika): Validated by RCTs showing berberine-containing extracts effective against acne-causing pathogens (P. acnes, S. epidermidis) and inflammatory acne
• Skin lightening and exfoliation (Varnya): Traditional scrub preparations validated by tyrosinase inhibition studies showing competitive enzyme inhibition
• Eye diseases with skin manifestation (Netra Roga): Traditional use supported by berberine’s demonstrated broad antimicrobial and anti-inflammatory activity
• Wound healing (Vrana): Supported by berberine’s anti-inflammatory and antimicrobial mechanisms promoting tissue repair

What do recent clinical trials show?

• Saeidi S, Ghanadian SM, Poostiyan N and others 2024. Evaluation of the effectiveness of Berberis integerrima Bunge root extract combined with spearmint essential oil in the treatment of acne vulgaris: A randomized controlled clinical trial. Journal of cosmetic dermatology. PMID 38545754 · doi:10.1111/jocd.16291
  Berberis root extract combined with spearmint oil demonstrated significant clinical improvement in acne vulgaris patients in a randomized controlled trial, validating the anti-acne potential of berberine-containing plants.
• Duda-Madej A, Lipska P, Viscardi S and others 2025. Targeting Skin Neoplasms: A Review of Berberine’s Anticancer Properties. Cells. PMID 40710294 · doi:10.3390/cells14141041
  Berberine demonstrated anticancer properties against various skin neoplasms through modulation of apoptotic pathways, cell cycle arrest, and inhibition of tumor proliferation signaling.

2 further claims previously listed here could not be traced to a published paper and have been removed. An absence here means we could not identify the source, not that no work exists.

Recent safety updates

• No serious hepatotoxicity linked to berberine despite wide-scale use; clinical trial biomarkers showed no toxic effects on liver, muscles, or kidneys. EFSA has called for additional data on long-term safety of berberine-containing food supplements
• Topical application is well-tolerated; adverse reactions in clinical trials with Berberis aristata root extract were minor and comparable to placebo group. Oral berberine may interact with CYP3A4-metabolized drugs

What is it made of?

Key Active Markers

• Berberine
• Palmatine
• Jatrorrhizine
• Berbamine
• Tannins
• Oxyberberine
• Karachine
• Taxilamine

Analytical Methods: HPLC fingerprinting, TLC (identity), LC-MS/MS (marker quantification)

Dosage forms and preparation

Dosage Forms: Churna (powder), Tablet, Capsule, Kashayam (decoction), Netra Bindu (eye drops), Taila (medicated oil), Kwath Ghana (solid extract)

Standard Dosage: 3-6g powder twice daily; 500mg standardized extract capsule twice daily; 50-100ml decoction twice daily; eye drops as directed

Bioavailability: Primary active berberine has notoriously low oral bioavailability (< 5%) due to extensive first-pass metabolism by CYP enzymes, P-glycoprotein efflux, and poor aqueous solubility. Enhancement strategies: co-administration with Pippali (piperine inhibits P-gp and CYP3A4, increasing berberine bioavailability 2-5 fold); solid lipid nanoparticle formulations increase AUC by 4-fold; berberine-phospholipid complex (phytosome) improves absorption; cyclodextrin inclusion complexes enhance solubility. Self-nanoemulsifying systems (SNEDDS) show 6-fold improvement in preclinical studies.

Optimal Timing: Before meals with warm water for metabolic conditions; after meals for GI conditions to reduce mucosal irritation

Standardized Extract: Standardized to NLT 5% berberine by HPLC (dried extract); concentrated extracts available at 85-97% berberine HCl. Extract ratio 10:1 to 20:1 typical for capsule formulations.

Shelf Life: 2 years (powder); 3 years (tablet/capsule); 1 year (eye drops after opening); 2 years (eye drops unopened)

Storage: Store in airtight, amber or opaque containers below 25 deg C, protected from light. Berberine degrades under UV exposure. Eye drops: store at 2-8 deg C, discard 28 days after opening.

Marker Compounds: Berberine, Palmatine, Jatrorrhizine, Berbamine, Oxyberberine, Columbamine

Extraction Methods

• Hydroalcoholic extraction (70:30 methanol:water)
• Aqueous decoction (traditional)
• Acid-water extraction (0.5% HCl)
• Supercritical CO2 extraction for berberine enrichment
• Ion-exchange chromatography for high-purity berberine isolation

Synergistic Combinations

• With Pippali (Piper longum) - piperine enhances berberine bioavailability 5x
• With Haridra (Curcuma longa) for synergistic anti-inflammatory action
• With Amalaki for diabetic management
• With Triphala for ophthalmic applications
• With Nimba for skin disorders and antimicrobial synergy